

# Press Release

For further information:

Peter Friedli  
Freigutstrasse 5  
8002 Zürich  
Tel: 044/283 29 00  
Email: peter.friedli@friedlicorp.ch

## New Venturetec with good results

### Results for the six months period ending March 31, 2007

#### **Net asset value increase by 31.9% - profit increase by 130.0% - share price increase by 13.4%**

Zürich, May 7, 2007. New Venturetec closed the first six months for fiscal year 2006/07, ended March 31, 2007, with a profit of USD 38,257,627.00 compared with USD 16,636,644.00 in the same period 2005/06, an increase of 130.0%. The net asset value per share increased from USD 23.97 to USD 31.62 which equals 31.9% during the reporting six month period; in CHF respectively from 30.00 to 38.36 or 27.9%. The share price in the same period increased from CHF 26.20 to CHF 29.70, or 13.4%.

The net gain on investments of the reporting period is USD 43,253,808.00 compared to USD 20,108,493.00 in the same period 2006. The main reasons for the increase are Osiris Therapeutics with USD 31,320,000 or 86.9%.and Basilea Pharmaceutica with USD 15,161,408.00 or 34.9%.

The operational progress of the portfolio companies is evident. As of March 31, 2007, New Venturetec had nine investments with seven investments valued higher than the investment costs and two below investment costs. The total amount of investments is USD 197,193,438.00 which results in an unrealized gain of USD 71,708,628.00. The investments are valued at 166.4% of the total paid-in and additional paid-in capital.

There was no management fee or board remuneration paid in the reporting period but rather accrued. Total operational costs for the first half of the fiscal year 2006/07 were USD 1,352,712.00 or 0.8% of the average net asset value.

The semi-annual report, including financial statements for the reporting period can be downloaded from [www.newventuretec.com](http://www.newventuretec.com).

New Venturetec is a publicly traded Swiss investment company (SWX:NEV) which invests directly in venture capital companies predominantly in the USA in the areas biotechnology and technology. As of March 31, 2007 71.7% of the total investments are in biotechnology and 28.6% in technology. The largest position is Osiris Therapeutics (NASDAQ:OSIR) with 36.2% of total investments.

The semi-annual conference takes place May 22, 2007 in the Hotel Park Hyatt, Beethovenstrasse 21, 8002 Zurich from 11.45h until 13.30h. The following companies will present: Iperia, E-centives and mPortal. Shareholders and guests are welcome. Please register under [www.newventuretec.com](http://www.newventuretec.com).